Abstract
Twelve previously untreated patients with histologically documented, metastatic, malignant melanoma were treated with the combination of procarbazine, vincristine, CCNU, and cyclophosphamide, with an objective response rate of 33%. The median survival time was 10 months for responders versus 5 months for nonresponders. Bone marrow suppression was the major toxic effect. Further clinical trials are needed to better assess the utility of this combination in advanced melanoma.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Agents / administration & dosage*
-
Antineoplastic Agents / adverse effects
-
Cyclophosphamide / administration & dosage
-
Drug Therapy, Combination
-
Humans
-
Lomustine / administration & dosage
-
Melanoma / drug therapy*
-
Middle Aged
-
Neoplasm Metastasis
-
Procarbazine / administration & dosage
-
Thrombocytopenia / chemically induced
-
Vincristine / administration & dosage
Substances
-
Antineoplastic Agents
-
Procarbazine
-
Vincristine
-
Lomustine
-
Cyclophosphamide